Developing a new generation of vaccine technologies

Current Projects

  • Rapidly engineered and highly scalable natural vaccine technology (billions of doses in a few months). Candidate vaccines can be manufactured in as little as 7 days; perfectly suited for validating new targets as the SARS-CoV-2 virus mutates. Read more here.

  • Creating personalized vaccines for cancer treatments by using a modular, rapidly engineered, hapten scaffolding vaccine system.

Latest Press Releases

As innovators, we are focused on creating ways of solving health problems every single day.

A scientist wearing safety goggles examining material using tweasers

WHO WE ARE


A Passionate Team of Scientists on a Mission

We are privately funded for Therapeutic Cancer Vaccine development with the vision of rapid vaccine deployment from "cancer target on a computer screen" to "active vaccine." Our customized vaccines will empower the patient's immune system to fight heterogeneous metastatic cancer tumors.

A scientist wearing safety goggles adjusting lab equipment

WHAT WE DO


Utilizing Advanced Technologies to Redefine Medicine

Our modular, scalable, room temperature vaccine platform is ideally suited to address many challenges of the current pandemic. We are focused on delivering a safe, robust, easy to distribute and inexpensive COVID-19 vaccine before the end of 2021.

World Class Team of Founders

  • Dr. Collin Collins, PhD

    Dr. Collin Collins, PhD

    Chief Scientific Officer (CSO)


    Senior Scientist, Vancouver Prostate Centre & UBC Professor, BC Canada. A world leader in cancer research with +250 peer-reviewed publications and known for co-inventing Next-Gen DNA sequencing technology. Previous positions include Lawrence Livermore National Laboratory, Lawrence Berkeley National Laboratory and the UCSF Comprehensive Cancer Center.​


    LinkedIn | GoogleScholar

  • Mr. Robert Bogden

    Mr. Robert Bogden

    Chief Executive Officer (CEO)


    Founded, ran, and successfully bootstrap financed a genomics company for +24 years with +$40M USD in revenues. Recognized by Deloitte and Touche as the 15th fastest growing technology company in Washington State and #442 in North America. On the team that discovered the BRCA-1 Breast Cancer gene in 1994. Has +17 years experience running a vaccine company inventing and deploying vaccines for agriculturally important animals.


    LinkedIn | GoogleScholar | ResearchGate

  • Dr. Keith Miller PhD

    Dr. Keith Miller PhD

    Chief Technology Officer (CTO)


    Over 24 years of biochemistry and immunology experience. Made a career of inventing hapten carrier vaccines for animals and humans. Specializes in protein design and engineering especially relating to vaccine immunogenicity and effector functions. Previous positions include a Senior Research Scientist for 12 years at Pacific Northwest National Laboratory developing novel fluorescent-based protein detection reagents for national security applications, and single-chain antibodies for the detection of a variety of cancers.


    LinkedIn | GoogleScholar

Vials of bottles labeled "VACCINE COVID-19"

OUR IMPACT


Benefiting the Community - Locally & Globally

Carefully analyzing SARS-CoV-2 virus mutations, we custom designed our modular vaccine to target areas of the virus less likely to mutate. As the pandemic spreads and the virus mutates, the targets mounted on our platform technology can be adapted quickly to address new threats.